Phase III, Open-Label, Multicenter International Study to Evaluate the Efficacy and Safety of an Octreotide Implant vs. Sandostatin LAR Depot in Patients With Acromegaly.
Phase of Trial: Phase III
Latest Information Update: 26 Sep 2013
At a glance
- Drugs Octreotide (Primary)
- Indications Acromegaly
- Focus Registrational; Therapeutic Use
- Sponsors Endo Pharmaceuticals Solutions
- 10 Jun 2017 Biomarkers information updated
- 26 Sep 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 22 Aug 2013 Primary endpoint 'Growth-hormone-levels' has not been met according to results published in the Journal of Clinical Endocrinology and Metabolism.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History